Armata Historical Income Statement
| ARMP Stock | USD 2.30 0.05 2.13% |
Historical analysis of Armata Pharmaceuticals income statement accounts such as Interest Expense of 2.8 M, Selling General Administrative of 11.1 M or Total Revenue of 4 M can show how well Armata Pharmaceuticals performed in making a profits. Evaluating Armata Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Armata Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Armata Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Armata Pharmaceuticals is a good buy for the upcoming year.
Armata |
About Armata Income Statement Analysis
Armata Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Armata Pharmaceuticals shareholders. The income statement also shows Armata investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Armata Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Armata Pharmaceuticals. It is also known as Armata Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Armata Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Armata Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Armata Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Armata Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Armata Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.At this time, Armata Pharmaceuticals' Non Operating Income Net Other is relatively stable compared to the past year.
Armata Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Armata Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Armata Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.6M | 1.1M | 1.2M | 892K | 972K | 1.1M | |
| Interest Expense | 931K | 628K | 64K | 29K | 2.6M | 2.8M | |
| Selling General Administrative | 9.3M | 8.0M | 8.3M | 7.4M | 11.6M | 11.1M | |
| Total Revenue | 31K | 823K | 4.5M | 5.5M | 4.5M | 4.0M | |
| Other Operating Expenses | 19.1M | 21.6M | 23.8M | 36.9M | 45.4M | 47.7M | |
| Operating Income | (19.8M) | (21.6M) | (23.8M) | (36.9M) | (40.9M) | (38.8M) | |
| Ebit | (19.8M) | (21.6M) | (23.8M) | (36.9M) | (40.9M) | (38.8M) | |
| Ebitda | (18.2M) | (20.4M) | (22.7M) | (36.1M) | (39.9M) | (37.9M) | |
| Total Operating Expenses | 19.1M | 21.6M | 23.8M | 36.9M | 11.6M | 15.8M | |
| Income Before Tax | (19.5M) | (22.2M) | (23.2M) | (36.9M) | (69.0M) | (65.6M) | |
| Total Other Income Expense Net | 273K | (594K) | 667K | 29K | (28.2M) | (26.7M) | |
| Net Income | (19.0M) | (22.8M) | (23.2M) | (36.9M) | (69.0M) | (65.6M) | |
| Income Tax Expense | (454K) | 634K | 64K | (29K) | (26.1K) | (24.8K) | |
| Research Development | 9.8M | 14.4M | 20.0M | 35.0M | 33.8M | 35.5M | |
| Interest Income | 96K | 28K | 5K | 29K | 125K | 118.8K | |
| Net Income Applicable To Common Shares | (19.5M) | (22.2M) | (23.2M) | (36.9M) | (33.2M) | (34.9M) | |
| Net Income From Continuing Ops | (19.5M) | (22.2M) | (23.2M) | (36.9M) | (59.5M) | (56.5M) | |
| Reconciled Depreciation | 1.4M | 1.1M | 1.2M | 892K | 924K | 976.3K |
Pair Trading with Armata Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Armata Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Armata Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Armata Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Armata Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Armata Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Armata Pharmaceuticals to buy it.
The correlation of Armata Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Armata Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Armata Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Armata Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Armata Stock Analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.